Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Cash & Equivalents (2021 - 2025)

Medicinova (MNOV) has disclosed Cash & Equivalents for 7 consecutive years, with $30.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $30.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.8 million, a N/A change, with the full-year FY2025 number at $30.8 million, changed N/A from a year prior.
  • Cash & Equivalents was $30.8 million for Q4 2025 at Medicinova, down from $32.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $77.8 million in Q2 2021 to a low of $30.8 million in Q4 2025.
  • A 5-year average of $53.6 million and a median of $52.0 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 30.01% in 2022, then dropped 1.9% in 2023.
  • Medicinova's Cash & Equivalents stood at $71.4 million in 2021, then decreased by 26.49% to $52.5 million in 2022, then fell by 2.87% to $51.0 million in 2023, then decreased by 17.1% to $42.3 million in 2024, then fell by 27.14% to $30.8 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Cash & Equivalents are $30.8 million (Q4 2025), $32.6 million (Q3 2025), and $34.3 million (Q2 2025).